mk 0663 has been researched along with indomethacin in 24 studies
Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (indomethacin) | Trials (indomethacin) | Recent Studies (post-2010) (indomethacin) |
---|---|---|---|---|---|
549 | 173 | 265 | 29,527 | 1,838 | 3,396 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (4.17) | 18.2507 |
2000's | 12 (50.00) | 29.6817 |
2010's | 10 (41.67) | 24.3611 |
2020's | 1 (4.17) | 2.80 |
Authors | Studies |
---|---|
Brideau, C; Chan, CC; Charleson, S; Deschênes, D; Dubé, D; Ethier, D; Fortin, R; Friesen, RW; Gauthier, JY; Girard, Y; Gordon, R; Greig, GM; Riendeau, D; Savoie, C; Visco, D; Wang, Z; Wong, E; Xu, LJ; Young, RN | 1 |
Byun, Y; Choi, JK; Choi, YH; Chung, S; Jeong, YS; Kim, JK; Kim, JY; Koh, HJ; Lee, KW; Lim, KM; Moh, JH; Noh, MS; Oh, YI; Park, YH; Shin, SS | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Boice, JA; Daikh, DI; Malmstrom, K; Molina, J; Mukhopadhyay, S; Ng, J; Schumacher, HR; Tate, GA | 1 |
Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT | 1 |
Antigua, J; Burton, R; Chen, E; Geba, GP; Londoño, J; Lund, M; Najarian, DK; Navarra, S; Ozturk, ZE; Petruschke, RA; Pryhuber, KG; Rubin, BR | 1 |
Azoubel, MC; Bezerra, D; Brito, GA; Menezes, AM; Oriá, RB; Ribeiro, RA | 1 |
Navarra, S; Rubin, BR; Smugar, SS; Tershakovec, AM; Yu, Q | 1 |
Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F | 1 |
Murphy, E; O'Connor, MB; Phelan, MJ; Regan, MJ | 1 |
Bressan, E; Tonussi, CR | 1 |
Norquist, JM; Schlesinger, N; Watson, DJ | 1 |
Anauate, MC; de Mello, SB; Torres, LM | 1 |
Sanyal, SN; Setia, S; Vaish, V | 1 |
Sanyal, SN; Setia, S | 2 |
Bao, CD; Chen, SL; Dai, Q; Gu, JR; Han, XH; Li, T; Li, XF; Li, ZG; Sun, LY; Wu, DH; Yang, NP; Zhang, MJ; Zhang, X | 1 |
Liu, P; Ma, JL; Wang, J; Zhang, S; Zhang, W; Zhang, Y | 1 |
Guan, M; Liu, S; Xu, L; Xue, Y | 1 |
Arfè, A; Castellsague, J; Garbe, E; Herings, R; Kollhorst, B; Lucchi, S; Masclee, GMC; Perez-Gutthann, S; Romio, S; Schade, R; Schink, T; Schuemie, MJ; Scotti, L; Straatman, H; Sturkenboom, MCJM; Valkhoff, VE; Varas-Lorenzo, C; Villa, M | 1 |
Bahra, A; Farag, M | 1 |
1 review(s) available for mk 0663 and indomethacin
Article | Year |
---|---|
Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gout; Humans; Indomethacin; Pain Measurement; Pyridines; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2016 |
6 trial(s) available for mk 0663 and indomethacin
Article | Year |
---|---|
Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.
Topics: Acute Disease; Adult; Aged; Arthritis, Gouty; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Gout Suppressants; Humans; Indomethacin; Male; Middle Aged; Pain; Pain Measurement; Pyridines; Sulfones; Treatment Outcome | 2002 |
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
Topics: Administration, Oral; Double-Blind Method; Drug Administration Schedule; Etoricoxib; Female; Gout; Gout Suppressants; Humans; Indomethacin; Male; Middle Aged; Pain; Pain Measurement; Pyridines; Sulfones; Treatment Outcome | 2004 |
Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout.
Topics: Acute Disease; Adult; Arthralgia; Arthritis; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Resistance; Etoricoxib; Female; Gout; Gout Suppressants; Humans; Indomethacin; Male; Middle Aged; Pyridines; Sulfones | 2007 |
Serum urate during acute gout.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Etoricoxib; Female; Gout; Gout Suppressants; Humans; Indomethacin; Male; Middle Aged; Pyridines; Sulfones; Treatment Outcome; Uric Acid; Young Adult | 2009 |
Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial.
Topics: Adult; Aged; Arthritis, Gouty; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; Humans; Indomethacin; Male; Middle Aged; Pyridines; Sulfones | 2013 |
Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial.
Topics: Adult; Arthritis, Gouty; Etoricoxib; Female; Humans; Indomethacin; Male; Pain Measurement; Prednisolone; Pyridines; Recurrence; Sulfones; Treatment Outcome | 2016 |
17 other study(ies) available for mk 0663 and indomethacin
Article | Year |
---|---|
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; CHO Cells; Cricetinae; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Structure-Activity Relationship | 1998 |
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Furans; Humans; In Vitro Techniques; Isoenzymes; Macrophages, Peritoneal; Male; Membrane Proteins; Mice; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pharmacological characterisation of a rat model of incisional pain.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Evaluation, Preclinical; Etoricoxib; Foot; Gabapentin; gamma-Aminobutyric Acid; Hindlimb; Hyperalgesia; Indomethacin; Male; Morphine; Muscle, Skeletal; Naproxen; Nociceptors; Pain Threshold; Pain, Postoperative; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sulfonamides; Sulfones; Time Factors; Weight-Bearing | 2004 |
[Rapidly acting and powerful antirheumatic drug now also approved in Germany. Arcoxia (etoricoxib, MSD)]].
Topics: Acute Disease; Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Approval; Etoricoxib; Gout; Humans; Indomethacin; Osteoarthritis; Pain Measurement; Pyridines; Sulfones | 2004 |
Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats.
Topics: Alveolar Bone Loss; Animals; Cyclooxygenase Inhibitors; Etoricoxib; Female; Gastric Mucosa; Indomethacin; Intestinal Mucosa; Periodontitis; Pyridines; Rats; Rats, Wistar; Sulfones | 2007 |
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; Drug Therapy, Combination; Etoricoxib; Hemorrhage; Ifosfamide; Immunoenzyme Techniques; Indomethacin; Male; Mesna; Pentoxifylline; Protective Agents; Pyridines; Rats; Rats, Wistar; Sulfones; Thalidomide | 2008 |
Primary stabbing headache can be responsive to etoricoxib, a selective COX-2 inhibitor.
Topics: Acute Disease; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Etoricoxib; Female; Headache Disorders, Primary; Humans; Indomethacin; Ophthalmic Nerve; Pain, Intractable; Pyridines; Sulfones; Treatment Outcome | 2008 |
Antiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Cyclooxygenase Inhibitors; Etoricoxib; Gastric Mucosa; Indomethacin; Knee Joint; Leukocytes; Lipopolysaccharides; Male; Pain Measurement; Piroxicam; Pyridines; Rats; Rats, Wistar; Sulfones; Synovial Fluid | 2008 |
Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Chemical Analysis; Blood Coagulation; Blood Platelets; Cinnamates; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Etoricoxib; Female; Glycosides; Harpagophytum; Humans; Indomethacin; Inflammation Mediators; Iridoids; Lipopolysaccharides; Nitric Oxide; Plant Extracts; Pyrans; Pyridines; Sulfones; Thromboxane B2 | 2010 |
Chemopreventive effects of NSAIDs as inhibitors of cyclooxygenase-2 and inducers of apoptosis in experimental lung carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; DNA Fragmentation; Drug Screening Assays, Antitumor; Etoricoxib; Female; Indomethacin; Lung; Lung Neoplasms; Membrane Proteins; Neoplasms, Experimental; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfones; Tumor Burden | 2012 |
Nuclear factor kappa B: a pro-inflammatory, transcription factor-mediated signalling pathway in lung carcinogenesis and its inhibition by nonsteroidal anti-inflammatory drugs.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Chemoprevention; Disease Models, Animal; Etoricoxib; Indomethacin; Lung Neoplasms; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Pyridines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Sulfones; Transcription Factors | 2012 |
Upregulation of intrinsic apoptotic pathway in NSAIDs mediated chemoprevention of experimental lung carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; DNA Fragmentation; Etoricoxib; Female; Indomethacin; Lung Neoplasms; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Sulfones; Up-Regulation | 2012 |
Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; Etoricoxib; Female; Humans; Indomethacin; Ketorolac; Lactones; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Factors; Sulfones | 2018 |
Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Etoricoxib; Headache; Headache Disorders; Humans; Indomethacin | 2022 |